

LIST OF CONTENTS

TITLE	i
ABSTRACT	ii
ABSTRAK	iv
ACKNOWLEDGEMENTS	vi
LIST OF CONTENTS	vii
LIST OF TABLES	x
LIST OF FIGURES	xii
LIST OF APPENDICES	xiv
LIST OF ABBREVIATIONS	xv
CHAPTER 1: INTRODUCTION	
1.1 General Introduction	1
1.2 Ethnic Group of Sarawak	4
1.3 Epidemiology of NPC	4
1.4 Classification of NPC	6
1.5 Aetiology Factors of NPC	7
1.5.1 Genetic factors	7
1.5.2 Environmental factors	9
1.6 Epstein-Barr Virus	11
1.7 EBV Structure	13
1.8 EBV Genome	14
1.9 EBV Infection	16
1.9.1 Latent infection	16
1.9.2 Lytic infection	19
1.10 EBV Antigens	20
1.10.1 Viral capsid antigen (VCA)	20
1.10.2 Early antigen (EA)	21
1.10.3 BHRF1 protein	23
1.11 EBV Serology in NPC	24
1.12 Epitope Mapping Using Synthetic Peptides	29
1.12.1 Multipin peptide synthesis	32
1.13 Objectives of This Study	33

CHAPTER 2: MATERIALS AND METHODS

2.1	Epstein-Barr Virus (EBV) Serology Assay	34
2.1.1	Cell lines	34
2.1.2	Solutions	34
	2.1.2.1 Culture medium	34
	2.1.2.2 Phosphate buffered saline (PBS)	35
	2.1.2.3 Sodium butyrate (NBA)	35
	2.1.2.4 12- <i>O</i> -tetradecanoyl phorbol 13-acetate (TPA)	35
2.1.3	Reviving and culturing of cells	36
2.1.4	Cell count and viability test	36
2.1.5	Induction of cells	36
2.1.6	Harvesting of induced cells	36
2.1.7	Serum samples	37
2.1.8	Immunofluorescence assay (IFA) for anti-EBV antibodies	38
2.2	Multipin Peptide Synthesis	39
2.2.1	Multipin peptide synthesis kit	39
2.2.2	Synthesis procedures	42
2.3	Multipin Enzyme-Linked Immunosorbent Assay (ELISA)	45
2.3.1	Solutions	45
	2.3.1.1 Phosphate buffered saline (PBS)	45
	2.3.1.2 Pre-coat buffer	46
	2.3.1.3 Conjugate diluent	46
	2.3.1.4 Substrate buffer solution	46
	2.3.1.5 <i>O</i> -phenylenediamine (OPD) substrate solution	46
	2.3.1.6 Disruption buffer	47
2.3.2	Serum samples	47
2.3.3	Multipin enzyme-linked immunosorbent assay (ELISA)	47

CHAPTER 3: RESULTS

3.1	Serum Samples	49
3.2	Immunofluorescence Assay (IFA) for Anti-EBV Antibodies	51
3.3	Titres and Distribution of Anti-EBV Antibodies	51
	3.3.1 Anti-EBV antibodies with respect to sex	58
	3.3.2 Anti-EBV antibodies with respect to ethnic groups	59
	3.3.3 Anti-EBV antibodies with respect to age groups	62
3.4	Determination of Cut-off Titres and Geometric Mean Titres	65
3.5	Comparison of Anti-EBV Serological Markers	66
3.6	Anti-EBV Serological Profiles	70
3.7	Multipin Peptide Synthesis of EBV BHRF1 Protein	72
	3.7.1 Multipin BHRF1 peptide ELISA	72
	3.7.2 IgA linear epitope of BHRF1 in NPC	73

CHAPTER 4: DISCUSSION	
4.1 Incidences of NPC in Sarawak	79
4.2 Detection of Anti-Epstein-Barr Virus Antibodies	81
4.2.1 Anti-EBV antibodies in NPC patients with respect to sex, ethnic groups and age	81
4.2.2 Sensitivity and specificity of anti-EBV antibody assays	82
4.2.3 Evaluation of anti-EBV antibody profile	85
4.3 Epitope Analysis of EBV BHRF1 Protein	88
CHAPTER 5: CONCLUSION	90
REFERENCES	91
APPENDICES	112

LIST OF TABLES

	Title	Page
Table 1.1 :	Population estimate by ethnic group.	4
Table 1.2 :	EBV-specific antigens and immunological response in patients with EBV-associated disease (Tam & Murray, 1990; Tam, 1991).	24
Table 1.3 :	Sensitivity and specificity of IgA/VCA in the diagnosis of NPC.	25
Table 1.4 :	Potential individual polypeptides of the antigen complexes of EBV for the diagnosis of NPC.	28
Table 3.1 :	Distribution of sera by sex.	49
Table 3.2 :	Distribution of sera by ethnic group.	50
Table 3.3 :	Distribution of sera by age group.	50
Table 3.4 :	Titres of IgA/VCA in NPC and non-NPC controls.	53
Table 3.5 :	Titres of IgG/VCA in NPC and non-NPC controls.	54
Table 3.6 :	Titres of IgA/EA in NPC and non-NPC controls.	55
Table 3.7 :	Titres of IgG/EA in NPC and non-NPC controls.	56
Table 3.8 :	GMTs and significance values between NPC and non-NPC controls.	57
Table 3.9 :	Geometric mean titre (GMT) and p value of anti-EBV antibodies in NPC patients with respect to sex.	58
Table 3.10 :	Geometric mean titre (GMT) of anti-EBV antibodies in NPC patients with respect to ethnic groups.	60
Table 3.11 :	Geometric mean titre (GMT) of anti-EBV antibodies in NPC patients with respect to age groups.	63
Table 3.12 :	Comparison of sensitivity and specificity of anti-EBV antibodies at different cut-off titres.	65
Table 3.13 :	Percentage of positivity and GMT of EBV serological markers in NPC and non-NPC controls.	66

Table 3.14 :	Anti-EBV serological profiles of NPC samples.	71
Table 3.15 :	Sensitivity and specificity of different combinations of 2 anti-EBV antibodies	71
Table 3.16 :	Major EBV BHRF1 peptides reactive with IgA in NPC sera.	77
Table 4.1 :	Various cut-off titre of EBV measured by IFA.	83
Table 4.2 :	Percentage of negative IgA/VCA titre in NPC confirmed patients.	86

LIST OF FIGURES

	Title	Page
Figure 1.1 :	The various states in Malaysia.	3
Figure 1.2 :	Herpesvirus structure and morphology (Ackermann & Berthiaume, 1995).	12
Figure 1.3 :	The structure of the Epstein-Barr virus genome with selected genes expressed during lytic and latency cycle (Cohen, 1997).	15
Figure 1.4 :	Solid phase peptide synthesis: a cyclical, three-step process.	31
Figure 2.1 :	The amino acids residues of BHRF1 protein. The alphabets represent single letter abbreviation for amino acids.	39
Figure 2.2 :	The Multipin Peptide Synthesis Kit (Chiron, Australia).	40
Figure 2.3 :	The numbering system of reaction tray.	41
Figure 3.1 :	Positive immunofluorescence assay (IFA) staining of IgA/EA with Raji cells (Magnification X200).	52
Figure 3.2 :	Negative immunofluorescence assay (IFA) staining of IgA/EA with Raji cells (Magnification X200).	52
Figure 3.3 :	Distribution of IgA/VCA titres in NPC and non-NPC controls.	53
Figure 3.4 :	Distribution of IgG/VCA titres in NPC and non-NPC controls.	54
Figure 3.5 :	Distribution of IgA/EA titres in NPC and non-NPC controls.	55
Figure 3.6 :	Distribution of IgG/EA titres in NPC and non-NPC controls.	56
Figure 3.7 :	GMT of anti-EBV antibodies by sex.	58
Figure 3.8 :	GMT of IgA/VCA by ethnic group.	60
Figure 3.9 :	GMT of IgG/VCA by ethnic group.	61

Figure 3.10 :	GMT of IgA/EA by ethnic group.	61
Figure 3.11 :	GMT of IgG/EA by ethnic group.	61
Figure 3.12 :	GMT of IgA/VCA by age group.	63
Figure 3.13 :	GMT of IgG/VCA by age group.	64
Figure 3.14 :	GMT of IgA/EA by age group.	64
Figure 3.15 :	GMT of IgG/EA by age group.	64
Figure 3.16 :	IgG/VCA and IgA/VCA titres in NPC samples.	67
Figure 3.17 :	IgG/VCA and IgA/EA titres in NPC samples.	68
Figure 3.18 :	IgG/VCA and IgG/EA titres in NPC samples.	69
Figure 3.19 :	Comparison of the mean absorbance between the conjugate test and 5 NPC sera.	72
Figure 3.20 :	BHRF1 peptide reactivity profile for 5 NPC sera and 1 control serum.	74
Figure 3.21 :	BHRF1 peptide reactivity profile of IgA antibodies in 3 NPC sera.	75
Figure 3.22 :	BHRF1 peptide reactivity profile of IgA antibodies in 2 NPC sera and 1 control serum.	76
Figure 3.23 :	The specific IgA antibody binding to BHRF1 peptides in NPC sera.	78